Semaglutide Doubles Risk for Nonarteritic Anterior Ischemic Optic Neuropathy
TUESDAY, Jan. 14, 2025 -- Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes, according to a study published online Dec. 18 in the International Journal of Retina and Vitreous.
Jakob Grauslund, D.M.Sci., Ph.D., M.D., from Odense University Hospital in Denmark, and colleagues prospectively evaluated the use of semaglutide and risk for NAION in people with type 2 diabetes. The analysis included 424,152 individuals (2018 to 2024) exposed (106,454 individuals) or not exposed (317,698 individuals) to once-weekly semaglutide.
The researchers found that semaglutide exposure was significantly associated with a higher incidence rate (0.228 versus 0.093 per 1,000 person-years) and independently predicted a higher risk for upcoming NAION (hazard ratio, 2.19), even when accounting for multiple other factors. Of the 67 persons exposed to semaglutide who developed NAION, there was a median time from first prescription to event of 22.2 months (interquartile range, 10.2 to 37.8 months).
"During five years of observation of all persons with type 2 diabetes in Denmark, use of once-weekly semaglutide independently more than doubled the risk of NAION," the authors write. "Given the irreversible nature of NAION, it is important to acknowledge this risk, and upcoming studies should aim to identify high-risk subgroups."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Hepatitis B Virus Immunity Linked to Reduced Risk for Diabetes
THURSDAY, Sept. 11, 2025 -- Hepatitis B virus (HBV) immunity in individuals without HBV infection is associated with a reduced risk for diabetes, according to a study published...
Adults With Learning Disabilities, New Diabetes Have Shorter Time to Insulin Initiation
THURSDAY, Sept. 4, 2025 -- Adults with learning disabilities and newly diagnosed type 2 diabetes (T2D) have better short-term glycemic control, but also faster progression to...
GLP-1 Receptor Agonists Linked to Reduced Risk for Developing Uveitis
TUESDAY, Sept. 2, 2025 -- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduction in the risk for developing uveitis, according to a study published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.